Arrowhead Pharmaceuticals’ (ARWR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a report published on Thursday,Benzinga reports. HC Wainwright currently has a $120.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2031 earnings at $9.61 EPS.

Several other equities analysts also recently commented on the company. Chardan Capital reiterated a “buy” rating and issued a $115.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 31st. Wall Street Zen raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. JPMorgan Chase & Co. boosted their price target on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Leerink Partners boosted their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a report on Wednesday, June 17th. Finally, B. Riley Financial upped their price objective on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $99.07.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $55.90 on Thursday. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals has a 12 month low of $36.57 and a 12 month high of $95.49. The firm has a market cap of $7.87 billion, a P/E ratio of -24.84 and a beta of 1.29. The company’s 50-day moving average price is $75.53 and its two-hundred day moving average price is $75.86.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. Arrowhead Pharmaceuticals’s quarterly revenue was up 171.0% on a year-over-year basis. During the same period last year, the firm posted ($1.26) EPS. On average, analysts anticipate that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Michael Perry sold 11,600 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares of the company’s stock, valued at $9,730,370.70. This represents a 9.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Adeoye Olukotun sold 2,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the transaction, the director directly owned 31,600 shares in the company, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The SEC filing for this sale provides additional information. 3.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ARWR. BlackRock Inc. bought a new stake in Arrowhead Pharmaceuticals during the second quarter worth $1,208,838,000. Baker BROS. Advisors LP boosted its position in Arrowhead Pharmaceuticals by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company’s stock worth $144,441,000 after purchasing an additional 504,883 shares during the last quarter. Siren L.L.C. boosted its position in Arrowhead Pharmaceuticals by 7.7% in the first quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock worth $101,290,000 after purchasing an additional 115,000 shares during the last quarter. Janus Henderson Group PLC grew its stake in Arrowhead Pharmaceuticals by 12.2% in the 1st quarter. Janus Henderson Group PLC now owns 1,436,990 shares of the biotechnology company’s stock valued at $90,119,000 after purchasing an additional 156,544 shares during the period. Finally, Pictet Asset Management Holding SA grew its stake in Arrowhead Pharmaceuticals by 23.8% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,273,266 shares of the biotechnology company’s stock valued at $79,612,000 after purchasing an additional 244,530 shares during the period. 62.61% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported interim Phase 1/2a results for ARO-MAPT, its investigational Alzheimer’s treatment. The drug reportedly crossed the blood-brain barrier and produced up to a 73% reduction in tau, a protein associated with Alzheimer’s disease. The results support the potential of Arrowhead’s TRiM platform for delivering RNA therapies into the central nervous system. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
• Positive Sentiment: UBS initiated coverage of ARWR with a Buy rating and a $109 price target, while Chardan Capital and HC Wainwright reiterated Buy ratings with targets of $115 and $120, respectively. The targets reflect analysts’ confidence in Arrowhead’s pipeline and potential long-term upside. Arrowhead Pharmaceuticals Receives a New Rating from UBS
• Positive Sentiment: HC Wainwright projects Arrowhead could earn $9.61 per share in fiscal 2031, a sharp contrast with the expected loss of $3.62 per share for the current fiscal year. This highlights the firm’s view that commercialization of Arrowhead’s pipeline could significantly improve future profitability.
• Neutral Sentiment: The ARO-MAPT findings are interim, early-stage results and will require confirmation in larger, later-stage trials before they can support regulatory approval or commercial revenue.
• Negative Sentiment: After the initial data-driven surge, investors may be taking profits and reassessing valuation. Arrowhead remains unprofitable, recently missed quarterly EPS expectations, and faces substantial clinical, regulatory, and execution risks.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.